Intelligent Diabetes Management System
Legal Citation
Summary of the Inventive Concept
A novel, integrated system combining Canagliflozin-based pharmaceutical compositions with cutting-edge technologies such as AI, IoT, blockchain, and advanced materials for personalized diabetes management, real-time monitoring, and targeted drug delivery.
Background and Problem Solved
The original patent disclosed a pharmaceutical composition comprising Canagliflozin, but it had limitations in terms of patient adherence, dosage optimization, and real-time monitoring. The new inventive concept addresses these limitations by integrating the patented composition with distinct technologies to create a more powerful system.
Detailed Description of the Inventive Concept
The system comprises a pharmaceutical composition of Canagliflozin, a wearable IoT device for monitoring glucose levels, and an AI-powered algorithm for predicting optimal dosage and administration schedules. Additionally, the system may include a blockchain-based data management platform for real-time monitoring of Canagliflozin efficacy, a novel, bio-absorbable material for targeted drug delivery, and a mobile application for remote patient monitoring and personalized coaching. The system's components interact to provide personalized guidance on medication adherence and lifestyle modifications.
Novelty and Inventive Step
The new claims introduce novel synergies between the pharmaceutical composition and advanced technologies, enabling real-time monitoring, personalized dosage optimization, and targeted drug delivery. These integrations are non-obvious and provide a significant improvement over the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include different IoT devices, AI algorithms, or blockchain platforms. Variations may include the use of different pharmaceutical compositions, materials, or dosage forms. The inventive concept can be adapted for other diseases or conditions requiring personalized management and monitoring.
Potential Commercial Applications and Market
The Intelligent Diabetes Management System has significant commercial potential in the pharmaceutical, healthcare, and technology industries. It can be marketed to pharmaceutical companies, healthcare providers, and patients seeking personalized diabetes management solutions.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical composition design, medical device technology, digital health systems, with expertise in diabetes management, drug delivery systems, and medical informatics
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or medical technology, possessing knowledge of drug formulation, medical device integration, and digital health platforms
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring technologies with pharmaceutical compositions represents a predictable evolution in personalized medicine. The source patent's focus on stable Canagliflozin compositions provides a clear foundation for exploring advanced delivery and monitoring technologies. The proposed variations represent logical extensions of existing pharmaceutical and digital health paradigms, utilizing well-established techniques in IoT, AI, and targeted drug delivery.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,559 |
|---|---|
| Title | Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof |
| Assignee(s) | Aurobindo Pharma Ltd |